Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on May 24, 2018. The report details a specific corporate event regarding the unregistered sale of equity securities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial metric disclosed is the capital raise event:
- Capital Raised: $2.5 million
- Shares Issued: 570,776 shares of Class A common stock
- Price Per Share: $4.38
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the exercise of a right under a letter agreement dated December 5, 2017, requiring the Investor to purchase the aforementioned shares. This transaction increased the company's cash position by $2.5 million and diluted existing shareholders by the issuance of 570,776 new shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the transaction was conducted pursuant to a prior agreement. The document references the full letter agreement attached as Exhibit 10.18 to the Company's Annual Report on Form 10-K filed on February 27, 2018, for further details.
Investor Verification Checklist
- Verify the terms of the letter agreement dated December 5, 2017, referenced in the filing.
- Review the Company's Form 10-K filed on February 27, 2018, specifically Exhibit 10.18.
- Confirm the post-transaction share count and dilution impact on existing holdings.
- Assess the company's cash runway following the $2.5 million infusion.